,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11111066,2995,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11111067,2995,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11111066,2995,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11111067,2995,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,411,2,1,,11111066,2995,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
5,411,2,1,,11111067,2995,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,444,1,1,,11111066,2995,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
7,444,1,1,,11111067,2995,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
8,445,3,1,,11111066,2995,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
9,445,3,1,,11111067,2995,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
10,446,1,1,,11111066,2995,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
11,446,1,1,,11111067,2995,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
12,447,1,1,,11111066,2995,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
13,447,1,1,,11111067,2995,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
14,448,1,2,,11111066,2995,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
15,448,1,2,,11111067,2995,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11111066,2995,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,450,1,2,,11111067,2995,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
18,451,1,2,,11111066,2995,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
19,451,1,2,,11111067,2995,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
20,526,1,1,,11111066,2995,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
21,526,1,1,,11111067,2995,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
22,530,1,1,,11111066,2995,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
23,530,1,1,,11111067,2995,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
24,584,1,3,,11111066,2995,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
25,584,1,3,,11111067,2995,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
26,585,1,4,,11111066,2995,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
27,585,1,4,,11111067,2995,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
28,587,1,5,,11111066,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
29,587,1,5,,11111067,2995,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
30,588,1,4,,11111066,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
31,588,1,4,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
32,589,1,3,,11111066,2995,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
33,589,1,3,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
34,590,1,3,,11111066,2995,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
35,590,1,3,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
36,591,1,4,,11111066,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
37,591,1,4,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
38,592,1,6,,11111066,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
39,592,1,6,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
40,593,1,4,,11111066,2995,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
41,593,1,4,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
42,594,1,4,,11111066,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
43,594,1,4,,11111067,2995,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
44,595,1,3,,11111066,2995,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
45,595,1,3,,11111067,2995,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
46,596,1,2,,11111066,2995,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
47,596,1,2,,11111067,2995,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
48,597,1,3,,11111066,2995,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
49,597,1,3,,11111067,2995,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
50,603,1,2,,11111066,2995,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
51,603,1,2,,11111067,2995,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
52,605,1,2,,11111066,2995,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
53,605,1,2,,11111067,2995,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
54,607,1,3,,11111066,2995,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
55,607,1,3,,11111067,2995,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
56,662,1,1,,11111066,2995,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
57,662,1,1,,11111067,2995,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
58,875,1,2,,11111066,2995,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
59,875,1,2,,11111067,2995,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
60,879,1,2,,11111066,2995,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
61,879,1,2,,11111066,2995,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
62,880,2,1,,11111067,2995,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
63,880,2,1,,11111067,2995,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,881,2,2,,11111066,2995,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
65,881,2,2,,11111067,2995,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
66,883,1,3,,11111066,2995,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
67,883,1,3,,11111067,2995,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
68,884,1,2,,11111066,2995,Active,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
69,884,1,2,,11111067,2995,Inconclusive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
70,885,1,2,,11111066,2995,Inactive,13435386.0,1576.0,19.9526,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
71,885,1,2,,11111067,2995,Inactive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
72,886,1,2,,11111066,2995,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
73,886,1,2,,11111066,2995,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
74,886,1,2,,11111067,2995,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
75,886,1,2,,11111067,2995,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
76,887,1,2,,11111066,2995,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
77,887,1,2,,11111067,2995,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
78,889,1,3,,11111066,2995,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
79,889,1,3,,11111067,2995,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
80,891,1,2,,11111066,2995,Active,40805836.0,1565.0,25.1189,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
81,891,1,2,,11111067,2995,Active,40805836.0,1565.0,3.9811,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
82,892,1,2,,11111066,2995,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
83,892,1,2,,11111067,2995,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
84,893,1,2,,11111066,2995,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
85,893,1,2,,11111066,2995,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
86,893,1,2,,11111067,2995,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
87,893,1,2,,11111067,2995,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
88,894,2,1,,11111067,2995,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
89,895,1,2,,11111066,2995,Inconclusive,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
90,899,1,2,,11111066,2995,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
91,899,1,2,,11111067,2995,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
92,900,1,3,,11111066,2995,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
93,900,1,3,,11111067,2995,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
94,901,1,2,,11111066,2995,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
95,901,1,2,,11111067,2995,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
96,902,1,2,,11111066,2995,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
97,902,1,2,,11111067,2995,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
98,912,1,2,,11111066,2995,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
99,912,1,2,,11111067,2995,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
100,914,1,3,,11111066,2995,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
101,914,1,3,,11111067,2995,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
102,915,1,3,,11111066,2995,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
103,915,1,3,,11111067,2995,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
104,917,1,3,,11111066,2995,Inconclusive,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
105,918,1,3,,11111066,2995,Active,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
106,923,1,2,,11111066,2995,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
107,923,1,2,,11111067,2995,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
108,924,1,2,,11111066,2995,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
109,924,1,2,,11111067,2995,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
110,925,1,2,,11111066,2995,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
111,925,1,2,,11111067,2995,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
112,926,1,2,,11111066,2995,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
113,926,1,2,,11111067,2995,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
114,927,1,3,,11111066,2995,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
115,927,1,3,,11111067,2995,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
116,928,1,2,,11111066,2995,Inconclusive,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
117,938,1,2,,11111066,2995,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
118,938,1,2,,11111067,2995,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
119,943,1,2,,11111066,2995,Active,18249941.0,25229.0,0.3162,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
120,944,1,2,,11111066,2995,Active,18249941.0,25229.0,2.8184,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
121,945,1,4,,11111066,2995,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
122,954,1,2,,11111066,2995,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
123,957,1,2,,11111066,2995,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
124,958,1,2,,11111066,2995,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
125,959,1,4,,11111066,2995,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
126,992,1,3,,11111066,2995,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
127,995,1,2,,11111066,2995,Inactive,66932916.0,5594.0,0.0079,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
128,995,1,2,,11111067,2995,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
129,997,1,2,,11111066,2995,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
130,998,1,2,,11111066,2995,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
131,1030,2,1,,11111067,2995,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
132,1195,1,2,,48415856,2995,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
133,1332,1,1,,49698852,2995,Inconclusive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
134,1379,1,2,,11111067,2995,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
135,1452,1,1,,11111066,2995,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
136,1452,1,1,,11111067,2995,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
137,1454,1,1,,11111067,2995,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
138,1457,1,1,,11111067,2995,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
139,1458,1,1,,11111067,2995,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
140,1467,1,3,,11111067,2995,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
141,1469,1,1,,11111067,2995,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
142,1471,2,1,,11111066,2995,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
143,1471,2,1,,11111067,2995,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
144,1476,2,1,,11111067,2995,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
145,1477,1,1,,11111067,2995,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
146,1478,2,1,,11111067,2995,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
147,1479,1,2,,11111067,2995,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
148,1487,1,1,,11111067,2995,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
149,1490,2,1,,11111067,2995,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
150,1519,1,3,,11111067,2995,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
151,1766,1,1,,11111067,2995,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
152,1766,1,1,,11111067,2995,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
153,1768,1,1,,11111067,2995,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
154,1768,1,1,,11111067,2995,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
155,1851,1,2,,11111066,2995,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
156,1851,1,2,,11111067,2995,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
157,1851,1,2,1.0,11111066,2995,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
158,1851,1,2,1.0,11111067,2995,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
159,1851,1,2,2.0,11111066,2995,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
160,1851,1,2,2.0,11111067,2995,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
161,1851,1,2,3.0,11111066,2995,Active,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
162,1851,1,2,3.0,11111067,2995,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
163,1851,1,2,4.0,11111066,2995,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
164,1851,1,2,4.0,11111067,2995,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
165,1851,1,2,5.0,11111066,2995,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
166,1851,1,2,5.0,11111067,2995,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
167,1865,1,1,,11111067,2995,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
168,1948,1,1,,11111067,2995,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
169,2062,1,2,,85209781,2995,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
170,2101,1,1,,11111067,2995,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
171,2107,1,1,,11111067,2995,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
172,2112,1,1,,11111067,2995,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
173,2147,1,1,,11111067,2995,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
174,2451,1,2,,11111067,2995,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
175,2472,1,2,,11111067,2995,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
176,2528,1,2,,11111067,2995,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
177,2546,1,1,,11111067,2995,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
178,2549,1,1,,11111067,2995,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
179,2551,1,1,,11111067,2995,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
180,2660,1,1,,90341801,2995,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
181,2662,2,1,,11111067,2995,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
182,2666,1,1,,90341801,2995,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
183,2667,1,1,,90341801,2995,Inconclusive,4826730.0,2475.0,14.6892,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
184,2668,1,1,,90341801,2995,Inconclusive,4826730.0,2475.0,26.1216,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
185,2669,1,1,,11111067,2995,Inconclusive,90903231.0,3064.0,35.4813,Potency,qHTS Assay Multiplex Screening to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (Protease relase),Confirmatory,,
186,2673,1,1,,11111067,2995,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection confirmation (ATP),Confirmatory,,
187,5444,7,1,,103169414,2995,Active,,,0.16,Ki,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Confirmatory,11266163.0,
188,6418,9,5,,103169414,2995,Active,112808.0,29595.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
189,6418,9,5,,103169414,2995,Active,112812.0,24473.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
190,6418,9,5,,103169414,2995,Active,112815.0,25075.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
191,6418,9,5,,103169414,2995,Active,112817.0,25187.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
192,6418,9,5,,103169414,2995,Active,112820.0,25323.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
193,6418,9,5,,103169414,2995,Active,398968.0,60448.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
194,6418,9,5,,103169414,2995,Active,398970.0,29581.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
195,6418,9,5,,103169414,2995,Active,461440.0,65032.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
196,6418,9,5,,103169414,2995,Active,543729.0,25689.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
197,6418,9,5,,103169414,2995,Active,543730.0,79247.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
198,6418,9,5,,103169414,2995,Active,1168221.0,64354.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
199,6418,9,5,,103169414,2995,Active,1168223.0,79246.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
200,6418,9,5,,103169414,2995,Active,2494928.0,25324.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
201,6418,9,5,,103169414,2995,Active,81868595.0,58963.0,0.35,IC50,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Confirmatory,10447960.0,
202,7783,3,4,,103169414,2995,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
203,8002,5,2,,103169414,2995,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
204,15708,6,1,,103169414,2995,Unspecified,,,,,Plasma clearance for the compound was determined.,Other,10447960.0,
205,19006,4,3,,103169414,2995,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
206,19262,5,1,,103169414,2995,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
207,19424,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
208,22345,3,3,,103169414,2995,Unspecified,,,,,Therapeutic plasma levels for the compound was evaluated.,Other,10447960.0,
209,22432,5,2,,103169414,2995,Unspecified,,,,,Volume of distribution in the plasma fluid was determined,Other,10447960.0,
210,22538,3,3,,103169414,2995,Unspecified,,,,,Half life period is estimated,Other,10447960.0,
211,23708,3,3,,103169414,2995,Unspecified,,,,,Partition coefficient (logP),Other,10447960.0,
212,23961,3,3,,103169414,2995,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
213,23971,3,3,,103169414,2995,Unspecified,,,,,logD (measured by HPLC) (as log k'),Other,6167716.0,
214,25866,3,3,,103169414,2995,Unspecified,,,,,Protonation constant of the compound.,Other,10447960.0,
215,26296,4,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
216,26300,3,5,,103169414,2995,Unspecified,,,,,log P values determined at PH 7.4,Other,10447960.0,
217,26362,4,3,,103169414,2995,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
218,26396,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD7.4),Other,6167716.0,
219,26518,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD) (HPLC),Other,6167716.0,
220,26520,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD) (HPLC),Other,6167716.0,
221,26538,3,3,,103169414,2995,Unspecified,,,,,log K was measured potentiometrically in Brij35 medium,Other,10447960.0,
222,27167,3,4,,103169414,2995,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
223,28233,3,3,,103169414,2995,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
224,28234,3,4,,103169414,2995,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
225,28235,3,3,,103169414,2995,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
226,28236,3,3,,103169414,2995,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
227,28679,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
228,28681,3,4,,103169414,2995,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
229,28921,3,3,,103169414,2995,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
230,28923,3,4,,103169414,2995,Unspecified,,,,,Effective permeability measured with Caco-2 cells,Other,11300874.0,
231,28924,3,3,,103169414,2995,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
232,28925,3,3,,103169414,2995,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
233,28926,3,3,,103169414,2995,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
234,28928,3,3,,103169414,2995,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
235,29337,3,3,,103169414,2995,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
236,29359,3,3,,103169414,2995,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
237,29423,3,4,,103169414,2995,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
238,29812,3,3,,103169414,2995,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
239,29845,3,4,,103169414,2995,Unspecified,,,,,Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.,Other,10841786.0,
240,29925,5,2,,103169414,2995,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
241,34291,6,3,,103169414,2995,Active,,,10.5,IC50,Compound was evaluated for in vitro inhibition of histamine activated adenylate cyclase in guinea pig cerebral cortex,Confirmatory,6105221.0,
242,34292,8,2,,103169414,2995,Active,,,0.35,Ki,Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase,Confirmatory,10447960.0,
243,34293,8,2,,103169414,2995,Active,,,0.32,Ki,Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase,Confirmatory,10447960.0,
244,36031,7,2,,103169414,2995,Active,,,0.00025,IC50,Compound was tested for its inhibitory activity against Alpha-1 adrenergic receptor,Confirmatory,10447960.0,
245,48900,3,3,,103169414,2995,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 1 mg/Kg,Other,11677127.0,
246,48901,3,3,,103169414,2995,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 2 mg/Kg,Other,11677127.0,
247,48902,3,3,,103169414,2995,Unspecified,,,,,Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 3 mg/Kg,Other,11677127.0,
248,64512,11,1,,103169414,2995,Active,,,3.0,Ki,Compound was tested for inhibition of [3H]WIN-35428 binding to the human (DAT) dopamine transporter,Confirmatory,10425082.0,
249,64525,7,1,,103169414,2995,Active,,,0.00049,Ki,In vitro competitive binding versus [N-methyl-3H]WIN-35428 in murine kidney cells transfected with cDNA for human dopamine transporter (DAT),Confirmatory,12620070.0,
250,64527,3,7,,103169414,2995,Unspecified,,,,,Ki uptake/Ki binding ratio was determined,Other,10425082.0,
251,65349,7,3,,103169414,2995,Unspecified,,,10.0,Ki,Ability to inhibit reuptake of dopamine ([3H]DA) at dopamine transporter of rat striatum,Confirmatory,14505672.0,
252,65494,8,2,,103169414,2995,Unspecified,,,4.0,Ki,Inhibitory constant towards reuptake of [125I]-12 from dopamine transporter in rat striatal membranes,Confirmatory,8182712.0,
253,87513,8,2,,103169414,2995,Active,,,0.0008,IC50,Compound tested for its inhibitory activity against Histamine H1 receptor,Confirmatory,10447960.0,
254,87880,7,6,,103169414,2995,Active,1346291.0,100729734.0,3.8,IC50,Inhibitory activity against brain adenylate cyclase Histamine H2 receptor,Confirmatory,10447960.0,
255,88008,4,11,,103169414,2995,Active,1346291.0,100729734.0,,,Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.,Other,10447948.0,
256,91481,4,7,,103169414,2995,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
257,91721,11,1,,103169414,2995,Active,,,0.13,IC50,Inhibition of binding of [3H]imipramine to imipramine receptor in rat brain,Confirmatory,1976813.0,
258,109908,3,3,,103169414,2995,Unspecified,,,,,Amphetamine antagonistic activity on peroral administration in mice; Value ranges from (29.4-65.9),Other,3806599.0,
259,109910,3,3,,103169414,2995,Unspecified,,,,,Antidepressant activity was assessed from the ability to antagonize reserpine-induced hypothermia on peroral administration in mice; Value ranges from 0.9-3.3.,Other,3806599.0,
260,109916,3,3,,103169414,2995,Unspecified,,,,,Antidepressant activity was assessed from the ability to antagonize reserpine-induced palpebral ptosis on peroral administration in mice; Value ranges from (1.3-3.4).,Other,3806599.0,
261,109922,3,3,,103169414,2995,Unspecified,,,,,Pentylenetetrazole antagonistic activity on peroral administration in mice; Value ranges from (24.5-41.4),Other,3806599.0,
262,110072,6,2,,103169414,2995,Unspecified,,,,,Ability to antagonise tetrabenazine (TBZ)-induced depression measured in mice for motor activity by subcutaneous administration,Other,3039136.0,
263,110190,6,2,,103169414,2995,Unspecified,,,,,Ability to antagonise tetrabenazine (TBZ)-induced depression measured in mice for ptosis by subcutaneous administration,Other,3039136.0,
264,112337,6,2,,103169414,2995,Unspecified,,,,,Evaluated for antidepressant activity by its ability to inhibit tetrabenazine-induced (TBZ) ptosis in mice,Other,6109027.0,
265,114139,6,2,,103169414,2995,Unspecified,,,,,Inhibition of tetrabenazine ptosis in mice following i.p. administration.,Other,6602886.0,
266,114156,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice,Other,3373495.0,
267,114157,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice,Other,3373495.0,
268,116717,6,2,,103169414,2995,Unspecified,,,,,Acute cytotoxicity was evaluated as LD50 in mice (ip),Other,3373495.0,
269,127789,6,2,,103169414,2995,Active,,,0.07,EC50,In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.,Confirmatory,4009610.0,
270,127795,6,2,,103169414,2995,Active,,,12.0,EC50,In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.,Confirmatory,4009610.0,
271,128144,7,2,,103169414,2995,Unspecified,,,,,Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
272,128147,7,2,,103169414,2995,Unspecified,,,,,Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo,Other,4009610.0,
273,129181,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after ip administration,Other,6970818.0,
274,129282,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after po administration,Other,6970818.0,
275,130112,6,2,,103169414,2995,Unspecified,,,,,Compound was evaluated for its antagonistic effect on the Tetrabenazine-induced ptosis following intravenous administration,Other,6088770.0,
276,130699,7,3,,103169414,2995,Unspecified,,,,,In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration,Other,6458703.0,
277,130700,7,4,,103169414,2995,Unspecified,,,,,In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration,Other,6458703.0,
278,130715,6,2,,103169414,2995,Unspecified,,,,,In vivo inhibition of uptake of nor epinephrine in mouse heart; value ranges from 0.5-3.5,Other,4009590.0,
279,132407,6,2,,103169414,2995,Unspecified,,,,,Inhibition of tetrabenazine-induced ptosis in mice following i.p. administration.,Other,7241520.0,
280,132665,6,3,,103169414,2995,Active,,,0.07,IC50,In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices,Confirmatory,6458703.0,
281,132666,6,4,,103169414,2995,Active,,,12.0,IC50,In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices,Confirmatory,6458703.0,
282,132965,4,3,,103169414,2995,Unspecified,,,,,In vivo antagonism of reserpine-induced hypothermia in the mice,Other,1976813.0,
283,135326,5,2,,103169414,2995,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
284,145400,7,2,,103169414,2995,Active,,,0.007359999999999999,Ki,Ability to inhibit reuptake of norepinephrine ([3H]NE) at norepinephrine transporter of rat parietal/occipital region,Confirmatory,14505672.0,
285,147591,8,2,,103169414,2995,Active,,,0.002,IC50,Compound was tested for its inhibitory activity against Noradrenaline receptor,Confirmatory,10447960.0,
286,156202,3,4,,103169414,2995,Unspecified,,,,,Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system,Other,10841786.0,
287,156204,3,4,,103169414,2995,Unspecified,,,,,Binding to POPC/GMI liposomes using biosensor system,Other,10841786.0,
288,159537,6,3,,103169414,2995,Active,,,0.42,IC50,Tested for in vitro reuptake inhibition of [3H]-5-hydroxy tryptamine in pig frontal synaptosomes.,Confirmatory,3806599.0,
289,159538,6,3,,103169414,2995,Active,,,6.1,IC50,Tested for in vitro reuptake inhibition of [3H]dopamine in pig striatal synaptosomes.,Confirmatory,3806599.0,
290,159539,6,3,,103169414,2995,Active,,,0.0032,IC50,Tested for in vitro reuptake inhibition of [3H]norepinephrine in pig occipital synaptosomes.,Confirmatory,3806599.0,
291,161281,10,5,,103169414,2995,Active,7531135.0,3757.0,1.51356,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
292,172542,3,3,,103169414,2995,Unspecified,,,,,In vivo noradrenergic responsiveness in the rat pineal gland at 10 mg/kg (ip) (chronic treatment),Other,1976813.0,
293,172545,5,2,,103169414,2995,Inactive,,,,,In vivo noradrenergic responsiveness in the rat pineal gland at 10 mg/kg (ip) (single treatment); No significant effect,Other,1976813.0,
294,173375,3,3,,103169414,2995,Unspecified,,,,,In vivo antagonism of histamine-induced ACTH release in the rat at 10 mg/kg (ip).,Other,1976813.0,
295,175362,3,4,,103169414,2995,Unspecified,,,,,Concentration required to inhibit [3H]- NE(norepinephrine) uptake in to rat cortical synaptosomes,Other,3373495.0,
296,177339,6,2,,103169414,2995,Unspecified,,,,,In vivo for the inhibition of muricidal activity. The effective dose (intraperitoneally) required for the activity was determined in rat,Other,7200144.0,
297,177982,6,2,,103169414,2995,Unspecified,,,,,Compound was screened in vivo for antidepressant activity by tryptamine seizure potentiation method in rat.,Other,7200144.0,
298,178197,6,2,,103169414,2995,Unspecified,,,,,Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally,Other,2565400.0,
299,178311,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity by tetrabenazine ptosis prevention in mice after oral administration,Other,6602886.0,
300,178314,6,2,,103169414,2995,Unspecified,,,,,Potentiation of head twitching induced by 5-HTP in pargyline-pretreated rats following i.p. administration.,Other,6602886.0,
301,178456,6,2,,103169414,2995,Unspecified,,,,,Antidepressant activity was measured by the potentiation of head twitching induced by 5-hydroxy-tryptophan in pargyline-pretreated rats after ip administration,Other,6970818.0,
302,179084,6,2,,103169414,2995,Active,,,0.011000000000000001,IC50,"Compound was tested for inhibition of uptake of [14C]5-HT (5-HT) into rat whole brain, in vitro.",Confirmatory,6708046.0,
303,179087,6,3,,103169414,2995,Active,,,0.025,IC50,"Compound was tested for inhibition of uptake of [14C]norepinephrine (NE) into rat brain hypothalamus, in vitro.",Confirmatory,6708046.0,
304,180129,6,2,,103169414,2995,Active,,,12.0,IC50,Inhibition of uptake of 5-HT in rat brain slices,Confirmatory,4009590.0,
305,180130,6,2,,103169414,2995,Active,,,12.0,IC50,Inhibition of uptake of Dopamine in rat brain slices,Confirmatory,4009590.0,
306,180132,6,5,,103169414,2995,Active,,,0.15,IC50,Inhibition of uptake of tritiated norepinephrine (NE) into rat brain synaptosomes,Confirmatory,1976813.0,
307,180133,6,5,,103169414,2995,Active,,,3.0,IC50,Inhibition of uptake of tritiated serotonin (5-HT) into rat brain synaptosomes,Confirmatory,1976813.0,
308,181517,6,3,,103169414,2995,Active,,,0.08,IC50,Ability to inhibit the uptake of norepinephrine (NE) by crude synaptosomes from rat whole brain,Confirmatory,6105221.0,
309,181518,6,3,,103169414,2995,Active,,,6.5,IC50,Ability to inhibit the uptake of serotonin (5-HT) by crude synaptosomes from rat whole brain,Confirmatory,6105221.0,
310,181678,6,3,,103169414,2995,Active,,,7.8,IC50,Inhibition of the reuptake of dopamine in rat corpora striata.,Confirmatory,2754707.0,
311,181680,6,3,,103169414,2995,Active,,,13.5,IC50,Inhibition of norepinephrine reuptake in rat whole brains minus cerebellar,Confirmatory,2754707.0,
312,181681,6,4,,103169414,2995,Unspecified,,,20.0,IC50,Inhibition of serotonin reuptake in rat whole brains without cerebellum,Confirmatory,2754707.0,
313,183050,4,2,,103169414,2995,Unspecified,,,,,"Compound was tested in vitro for beta -adrenergic sensitivity and administered to rats at 10 mg/kg, perorally, twice daily for 10 days.",Other,7200144.0,
314,183727,3,3,,103169414,2995,Unspecified,,,,,Inhibitory activity of compound against ability of NE to enhance the inhibition produced by GABA after 1 i.p. injection of 10 mg/kg administered (acute treatment),Other,3373495.0,
315,183728,3,3,,103169414,2995,Unspecified,,,,,Inhibitory activity of compound against ability of NE to enhance the inhibition produced by GABA after ip injection of 10 mg/kg administered once a day for 21 days (chronic treatment),Other,3373495.0,
316,185583,3,4,,103169414,2995,Unspecified,,,,,Percent inhibitory activity caused by norepinephrine after 1 i.p. injection of 10 mg/kg administered (acute treatment),Other,3373495.0,
317,185584,3,4,,103169414,2995,Unspecified,,,,,Percent inhibitory activity caused by norepinephrine after ip injection of 10 mg/kg administered once a day for 21 days (chronic treatment),Other,3373495.0,
318,186205,3,3,,103169414,2995,Unspecified,,,,,Log (1/ED50) was measured as histamine releasing activity in rat mast cells; log(1/ED50*10e-3).,Other,6167716.0,
319,189474,3,3,,103169414,2995,Unspecified,,,,,Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.,Other,6167716.0,
320,195552,6,3,,103169414,2995,Active,,,1.7,IC50,Inhibition of neuronal uptake of Noradrenaline in rat brain homogenate,Confirmatory,9357518.0,
321,196059,7,3,,103169414,2995,Active,,,6.53,Ki,Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes,Confirmatory,3039136.0,
322,196062,7,3,,103169414,2995,Active,,,0.00065,Ki,Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes,Confirmatory,3039136.0,
323,196063,7,3,,103169414,2995,Active,,,0.182,Ki,Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes,Confirmatory,3039136.0,
324,204709,7,3,,103169414,2995,Active,,,0.163,Ki,Ability to inhibit reuptake of serotonin ([3H]5-HT) at serotonin transporter of rat midbrian,Confirmatory,14505672.0,
325,205267,9,2,,103169414,2995,Active,,,2.4,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
326,205268,4,7,,103169414,2995,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
327,212885,3,3,,103169414,2995,Unspecified,,,,,Compound dose that causes lethality (acute toxicity) was determined by administering perorally in mice.,Other,3806599.0,
328,221731,7,2,,103169414,2995,Unspecified,,,,,"Ability to kill 50% of the animals after 24h, when administered perorally",Other,3806614.0,
329,222978,7,2,,103169414,2995,Unspecified,,,,,Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration,Other,3806614.0,
330,223123,7,2,,103169414,2995,Unspecified,,,,,Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration,Other,3806614.0,
331,223128,7,2,,103169414,2995,Unspecified,,,,,"Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.",Other,3806614.0,
332,224550,3,3,,103169414,2995,Unspecified,,,,,Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.,Other,3806614.0,
333,227718,7,1,,103169414,2995,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
334,237685,4,3,,103169414,2995,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
335,238633,8,5,,103169414,2995,Unspecified,128613.0,24898.0,10.0,Ki,Inhibitory constant against reuptake of [3H]-DA at dopamine transporter of rat striatal membranes,Confirmatory,15863297.0,
336,238634,8,5,,103169414,2995,Active,81907603.0,,0.007359999999999999,Ki,Inhibitory constant against reuptake of [3H]NE at norepinephrine transporter of rat parietal-occipital cortex,Confirmatory,15863297.0,
337,238667,8,5,,103169414,2995,Active,400629.0,25553.0,0.163,Ki,Inhibitory constant against reuptake of [3H]5-HT at serotonin transporter of rat midbrain cortex,Confirmatory,15863297.0,
338,243151,7,2,,103169414,2995,Active,,,1.38038,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
339,284828,8,5,,103169414,2995,Active,128616.0,6530.0,0.001,Ki,Binding affinity at NET,Confirmatory,17123820.0,
340,288184,9,1,,103169414,2995,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
341,288185,7,1,,103169414,2995,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
342,288186,3,4,,103169414,2995,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed,Other,17418579.0,
343,288187,3,4,,103169414,2995,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed,Other,17418579.0,
344,288190,3,4,,103169414,2995,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed,Other,17418579.0,
345,288192,3,4,,103169414,2995,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
346,288193,3,4,,103169414,2995,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
347,288194,3,5,,103169414,2995,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
348,289402,6,2,,103169414,2995,Unspecified,,,80.0,IC50,Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay,Confirmatory,17690258.0,
349,289403,11,2,,103169414,2995,Active,266667.0,6531.0,47.9,IC50,Inhibition of [3H]dopamine uptake in human wild type DAT transfected HEK293 cells,Confirmatory,17690258.0,
350,289404,6,3,,103169414,2995,Unspecified,,,50.5,IC50,Inhibition of [3H]dopamine uptake in human DAT P387A mutant transfected HEK293 cells,Confirmatory,17690258.0,
351,289405,6,3,,103169414,2995,Active,,,17.7,IC50,Inhibition of [3H]dopamine uptake in human DAT I390V mutant transfected HEK293 cells,Confirmatory,17690258.0,
352,289406,6,3,,103169414,2995,Active,,,9.9,IC50,Inhibition of [3H]dopamine uptake in human DAT F472L mutant transfected HEK293 cells,Confirmatory,17690258.0,
353,289407,11,2,,103169414,2995,Active,400630.0,6532.0,0.10800000000000001,IC50,Inhibition of [3H]serotonin uptake in human wild type SERT transfected HEK293 cells,Confirmatory,17690258.0,
354,289408,6,3,,103169414,2995,Active,,,0.0524,IC50,Inhibition of [3H]serotonin uptake in human SERT K490T mutant transfected HEK293 cells,Confirmatory,17690258.0,
355,289409,3,3,,103169414,2995,Active,,,,,Inhibition of [3H]leucine transport activity of LeuT in proteoliposomes by scintillation proximity assay,Other,17690258.0,
356,311934,3,3,,103169414,2995,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
357,311935,3,4,,103169414,2995,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
358,327169,3,3,,103169414,2995,Unspecified,,,,,Apparent permeability across parallel artificial membrane,Other,18348514.0,
359,327170,4,6,,103169414,2995,Unspecified,113576.0,213.0,851.138,Kd,Binding affinity to human serum albumin by PAMPA method,Confirmatory,18348514.0,
360,330659,3,3,,103169414,2995,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 50 uM,Other,18033297.0,
361,330661,3,3,,103169414,2995,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 200 uM,Other,18033297.0,
362,330664,3,3,,103169414,2995,Unspecified,,,,,Effect on life span of Caenorhabditis elegans at 10 uM,Other,18033297.0,
363,338159,9,1,,103169414,2995,Active,,,0.58,Ki,Displacement of [3H]DMI from norepinephrine transporter,Confirmatory,8496700.0,
364,338196,3,7,,103169414,2995,Unspecified,,,,,Displacement of [3H]DMI from norepinephrine transporter assessed as specific binding relative to total binding,Other,8496700.0,
365,339392,8,5,,103169414,2995,Active,128616.0,6530.0,0.0021,Ki,Displacement of [3H]nisoxetine from human norepinephrine transporter expressed in MDCK-Net6 cells,Confirmatory,18557608.0,
366,339393,8,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of norepinephrine uptake at human norepinephrine transporter expressed in MDCK-Net6 cells,Confirmatory,18557608.0,
367,339420,3,3,,103169414,2995,Unspecified,,,,,"Antidepressant activity in mouse assessed as decrease in immobility time at 8 mg/kg, ip",Other,18557608.0,
368,339421,3,3,,103169414,2995,Unspecified,,,,,"Antidepressant activity in mouse assessed as decrease in immobility time at 16 mg/kg, ip",Other,18557608.0,
369,339422,3,3,,103169414,2995,Active,,,,,"Antinociceptive activity in CD1 mouse assessed as reduction in p-phenylquinone-induced abdominal constricitions at 10 mg/kg, sc after 60 mins relative to control",Other,18557608.0,
370,339423,3,3,,103169414,2995,Active,,,,,"Antinociceptive activity in CD1 mouse assessed as reduction in p-phenylquinone-induced abdominal constricitions at 30 mg/kg, sc after 60 mins relative to control",Other,18557608.0,
371,343685,3,3,,103169414,2995,Unspecified,,,,,Ratio of drug level in brain to blood in Wistar rat,Other,18558667.0,
372,349880,8,1,,103169414,2995,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
373,351887,9,5,,103169414,2995,Active,400630.0,6532.0,0.064,IC50,Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells,Confirmatory,17846138.0,
374,351888,9,5,,103169414,2995,Unspecified,266667.0,6531.0,82.0,IC50,Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells,Confirmatory,17846138.0,
375,351890,8,1,,103169414,2995,Active,,,16.6,IC50,Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum Dd2 infected human erythrocytes by SYBR green assay,Confirmatory,17846138.0,
376,351891,6,2,,103169414,2995,Active,,,22.9,IC50,Cytotoxicity against C57BL/6J mouse splenocytes after 72 hrs by alamar blue assay,Confirmatory,17846138.0,
377,351893,8,1,,103169414,2995,Active,,,11.4,IC50,Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by SYBR green assay,Confirmatory,17846138.0,
378,351894,9,5,,103169414,2995,Active,128616.0,6530.0,0.0042,IC50,Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells,Confirmatory,17846138.0,
379,351896,3,3,,103169414,2995,Unspecified,,,,,Chemosensitizing activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as IC50 ratio chloroquine +/- 500nM by SYBR green assay,Other,17846138.0,
380,351897,3,3,,103169414,2995,Unspecified,,,,,Chemosensitizing activity after 72 hrs against chloroquine-resistant Plasmodium falciparum Dd2 infected human erythrocytes as IC50 ratio chloroquine +/- 500 nM by SYBR green assay,Other,17846138.0,
381,352215,8,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells,Confirmatory,19329313.0,
382,357470,5,2,,103169414,2995,Active,,,0.000741,IC50,Inhibition of [3H]NE uptake at human NET EL2 chimera mutant expressed in african green monkey COS1 cells after 48 hrs,Confirmatory,17428804.0,
383,357471,3,10,,103169414,2995,Active,128616.0,6530.0,,,Inhibition of [3H]NE uptake at human wild type NET expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
384,357472,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET E122A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
385,357473,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET L169T mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
386,357474,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET N170E mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
387,357475,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D175A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
388,357476,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET G177N mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
389,357477,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET H178N mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
390,357478,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET K189H mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
391,357479,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET N192D mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
392,357480,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET G193S mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
393,357481,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET E223Q mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
394,357482,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET H228D mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
395,357483,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET L232P mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
396,357484,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET Q234R mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
397,357485,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D298A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
398,357486,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET E304A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
399,357487,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D310A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
400,357488,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D378A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
401,357489,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET E382A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
402,357490,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET A384P mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
403,357491,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET E393A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
404,357492,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET K463N mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
405,357493,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET L469A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
406,357494,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET L469F mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
407,357495,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET T474H mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
408,357496,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET L543P mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
409,357497,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D546G mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
410,357498,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET D547A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
411,357499,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET P552D mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
412,357500,3,4,,103169414,2995,Active,,,,,Inhibition of [3H]NE uptake at human NET W556A mutant expressed in african green monkey COS1 cells after 48 hrs,Other,17428804.0,
413,360444,4,9,,103169414,2995,Inactive,128613.0,24898.0,,,Displacement of [3H]RTI82 from DAT in rat striatal membrane,Other,17255098.0,
414,361985,3,4,,103169414,2995,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
415,361986,3,4,,103169414,2995,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
416,373867,6,3,,103169414,2995,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
417,378466,11,2,,103169414,2995,Active,128616.0,6530.0,0.00093,IC50,Displacement of [125I]RTI-55 from human NET expressed in MDCK cell membrane,Confirmatory,16989524.0,
418,386623,4,8,,103169414,2995,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
419,386625,9,5,,103169414,2995,Unspecified,313104181.0,6580.0,56.8,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
420,387487,8,5,,103169414,2995,Active,128616.0,6530.0,0.0039,IC50,Inhibition of norepinephrine uptake at human NET expressed in MDCK cells,Confirmatory,18771916.0,
421,395325,3,3,,103169414,2995,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
422,395328,3,3,,103169414,2995,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
423,397743,11,2,,103169414,2995,Active,7531135.0,3757.0,1.39,IC50,Inhibition of human ERG channel,Confirmatory,19534531.0,
424,404304,3,10,,103169414,2995,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
425,408340,8,5,,103169414,2995,Active,7531135.0,3757.0,1.38038,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
426,410149,8,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells,Confirmatory,18951020.0,
427,420787,3,10,,103169414,2995,Unspecified,1168222.0,3359.0,,,Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM,Other,19144451.0,
428,425652,7,2,,103169414,2995,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
429,425653,7,2,,103169414,2995,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
430,427196,8,1,,103169414,2995,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
431,427197,8,1,,103169414,2995,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
432,427198,8,1,,103169414,2995,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
433,431485,7,2,,103169414,2995,Active,,,0.00511,Ki,Inhibition of [3H]norepinephrine reuptake at norepinephrine transporter,Confirmatory,19791802.0,
434,431881,8,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of [3H]norepinephrine uptake at human NET expressed in MDCK-Net6 cells by scintillation counting,Confirmatory,19722525.0,
435,431882,8,5,,103169414,2995,Active,128616.0,6530.0,,IC50,Inhibition of [3H]nisoxetine binding to human NET expressed in MDCK-Net6 cells by plate scintillation counting,Confirmatory,19722525.0,
436,441348,7,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of human NET expressed in MDCK-Net6 cells,Confirmatory,19713106.0,
437,444050,7,1,,103169414,2995,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
438,444051,6,2,,103169414,2995,Unspecified,,,,,Total clearance in human,Other,20070106.0,
439,444052,6,2,,103169414,2995,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
440,444053,6,2,,103169414,2995,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
441,444054,6,1,,103169414,2995,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
442,444055,3,3,,103169414,2995,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
443,444056,3,3,,103169414,2995,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
444,444057,3,3,,103169414,2995,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
445,444058,6,2,,103169414,2995,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
446,446936,7,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of norepinephrine reuptake at human NET expressed in MDCK-Net6 cells,Confirmatory,19632110.0,
447,452389,6,2,,103169414,2995,Active,,,0.0006,Ki,Inhibition of norepinephrine reuptake at NET,Confirmatory,19836247.0,
448,455986,3,5,,103169414,2995,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
449,459949,7,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells,Confirmatory,20131864.0,
450,459950,9,2,,103169414,2995,Active,128616.0,6530.0,0.0033,IC50,Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells,Confirmatory,20131864.0,
451,463106,1,2,,90341801,2995,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
452,469403,5,1,,103169414,2995,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
453,476929,3,3,,103169414,2995,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
454,481439,3,4,,103169414,2995,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
455,481440,3,4,,103169414,2995,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,20373811.0,
456,481441,3,6,,103169414,2995,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
457,481442,3,6,,103169414,2995,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
458,481444,3,4,,103169414,2995,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
459,481446,5,1,,103169414,2995,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
460,481497,7,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of human NET transfected in MDCK-Net6 cells,Confirmatory,20378347.0,
461,483451,7,5,,103169414,2995,Active,128616.0,6530.0,,IC50,Inhibition of human NET-mediated norepinephrine uptake in MDCK-Net6 cells,Confirmatory,20462211.0,
462,483452,7,5,,103169414,2995,Active,128616.0,6530.0,,IC50,Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells,Confirmatory,20462211.0,
463,485281,1,1,,11111067,2995,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
464,485290,1,1,,11111067,2995,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
465,485295,1,2,,90341801,2995,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
466,485297,1,1,,90341801,2995,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
467,485298,1,1,,90341801,2995,Inactive,,,23.1093,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
468,485313,1,2,,90341801,2995,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
469,485342,1,2,,90341801,2995,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
470,485345,1,2,,90341801,2995,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
471,485366,1,2,,90341801,2995,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
472,485368,1,2,,90341801,2995,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
473,488772,1,1,,90341801,2995,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
474,488773,1,2,,90341801,2995,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
475,488816,1,1,,90341801,2995,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
476,488837,1,1,,90341801,2995,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
477,488949,1,2,,90341801,2995,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
478,488953,1,1,,90341801,2995,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
479,488978,1,1,,90341801,2995,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
480,488981,1,1,,90341801,2995,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
481,488982,1,1,,90341801,2995,Inactive,4503383.0,1812.0,1.8355,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
482,488983,1,1,,90341801,2995,Inconclusive,4503383.0,1812.0,11.2202,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
483,492961,1,1,,11111067,2995,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
484,493106,1,1,,90341801,2995,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
485,493107,1,1,,90341801,2995,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
486,493153,1,1,,90341801,2995,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
487,493153,1,1,,90341801,2995,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
488,493164,1,2,,90341801,2995,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
489,493164,1,2,,90341801,2995,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
490,493164,1,2,,90341801,2995,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
491,496819,4,2,,103169414,2995,Active,,,12.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
492,504327,1,1,,11111067,2995,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
493,504327,1,1,,90341801,2995,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
494,504332,1,1,,11111067,2995,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
495,504332,1,1,,90341801,2995,Inconclusive,168985070.0,,33.5875,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
496,504536,1,1,,90341801,2995,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
497,504547,1,1,,90341801,2995,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
498,504548,1,2,,90341801,2995,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
499,504749,1,3,,11111067,2995,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
500,504749,1,3,1.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,2.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,3.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,4.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,5.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,6.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,7.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,8.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,9.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,10.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,11.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,12.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504749,1,3,13.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
513,504749,1,3,14.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
514,504749,1,3,15.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
515,504749,1,3,16.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
516,504749,1,3,17.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,18.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,19.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,20.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,21.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,22.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,23.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,24.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,25.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,26.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,27.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504749,1,3,28.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
528,504749,1,3,29.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
529,504749,1,3,30.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
530,504749,1,3,31.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
531,504749,1,3,32.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
532,504749,1,3,33.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
533,504749,1,3,34.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
534,504749,1,3,35.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
535,504749,1,3,36.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
536,504749,1,3,37.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
537,504749,1,3,38.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
538,504749,1,3,39.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
539,504749,1,3,40.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
540,504749,1,3,41.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
541,504749,1,3,42.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
542,504749,1,3,43.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
543,504749,1,3,44.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
544,504749,1,3,45.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
545,504749,1,3,46.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
546,504749,1,3,47.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
547,504749,1,3,48.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
548,504749,1,3,49.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
549,504749,1,3,50.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
550,504749,1,3,51.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
551,504749,1,3,52.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
552,504749,1,3,53.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
553,504749,1,3,54.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
554,504749,1,3,55.0,11111067,2995,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
555,504749,1,3,56.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
556,504749,1,3,57.0,11111067,2995,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
557,504749,1,3,58.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
558,504749,1,3,59.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
559,504749,1,3,60.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
560,504749,1,3,61.0,11111067,2995,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
561,504810,1,2,,90341801,2995,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
562,504812,1,2,,90341801,2995,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
563,504832,1,1,,11111067,2995,Inconclusive,,,6.4241,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
564,504834,1,1,,11111067,2995,Inconclusive,,,6.4241,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
565,504836,1,2,,90341801,2995,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
566,504845,1,1,,90341801,2995,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
567,504847,1,1,,11111067,2995,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
568,504847,1,1,,90341801,2995,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
569,504865,1,1,,11111067,2995,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
570,504865,1,1,,90341801,2995,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
571,515780,5,1,,103169414,2995,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
572,516915,2,4,,103169414,2995,Unspecified,,,,,"Increase of normetanephrine level in NMRI mouse cortex at 10 mg/kg, ip after 1 hr microwave irradiation",Other,20809632.0,
573,537543,6,5,,103169414,2995,Active,81890335.0,,0.00078,Ki,Displacement of [3H]nisoxetine from rat NET in rat cerebral cortex,Confirmatory,20945906.0,
574,537544,6,5,,103169414,2995,Unspecified,17365993.0,85268.0,5.0,Ki,Displacement of [3H]N-R-methylhistamine from rat H3 receptor,Confirmatory,20945906.0,
575,537545,6,5,,103169414,2995,Unspecified,17367264.0,11255.0,5.0,Ki,Displacement of [3H]N-R-methylhistamine from human H3 receptor isolated from C6 cells,Confirmatory,20945906.0,
576,537546,6,5,,103169414,2995,Active,128616.0,6530.0,0.0008300000000000001,Kd,Inhibition of human NET,Confirmatory,20945906.0,
577,537571,5,3,,103169414,2995,Active,,,0.02,Ki,Inhibition of SERT,Confirmatory,20945906.0,
578,540209,4,3,,103169414,2995,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
579,540210,4,3,,103169414,2995,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
580,540211,2,5,,103169414,2995,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
581,540212,4,3,,103169414,2995,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
582,540213,4,3,,103169414,2995,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
583,540256,1,2,,90341801,2995,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
584,540276,1,2,,11111066,2995,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
585,540276,1,2,,11111067,2995,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
586,540276,1,2,,50100220,2995,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
587,540276,1,2,,50104283,2995,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
588,540276,1,2,,90341801,2995,Inconclusive,420597.0,,8.1961,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
589,550800,2,5,,103169414,2995,Unspecified,,,,,"Ratio of drug level in whole brain to plasma of mouse at 30 mg/kg, po after 120 mins",Other,21093273.0,
590,576612,7,5,,103169414,2995,Active,7531135.0,3757.0,1.38038,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
591,578393,1,3,,103169414,2995,Active,,,,,"Antidepressant activity in mouse assessed as immobility at 100 mg/kg, po measured after 30 mins",Other,21310609.0,
592,578396,1,3,,103169414,2995,Active,,,,,"Antidepressant activity in mouse assessed as reduction of immobility duration pretreated for 30 mins at 100 mg/kg, po by tail suspension test",Other,21310609.0,
593,588208,2,3,,103169414,2995,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
594,588209,2,3,,103169414,2995,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
595,588210,2,4,,103169414,2995,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
596,588220,2,3,,103169414,2995,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
597,588349,1,1,,90341801,2995,Inconclusive,,,22.3872,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
598,588378,1,1,,90341801,2995,Inconclusive,171543895.0,6311.0,14.1254,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
599,588453,1,1,,90341801,2995,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
600,588456,1,1,,90341801,2995,Inactive,8659577.0,58819.0,8.4368,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
601,588579,1,1,,11111067,2995,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
602,588579,1,1,,90341801,2995,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
603,588795,1,1,,90341801,2995,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
604,589038,1,10,,103169414,2995,Unspecified,84028191.0,1565.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
605,592681,1,4,,103169414,2995,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
606,602332,1,1,,11111067,2995,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
607,602332,1,1,,90341801,2995,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
608,619830,5,5,,103169414,2995,Active,128616.0,6530.0,0.0034,IC50,Inhibition of human NET expressed in MDCK-Net6 cells assessed as inhibition of norepinephrine uptake,Confirmatory,21916421.0,
609,619831,5,5,,103169414,2995,Active,128616.0,6530.0,,IC50,Displacement of [3H]nisoxetine from human NET expressed in MDCK-Net6 cells,Confirmatory,21916421.0,
610,620399,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA,Other,21871694.0,
611,624030,1,2,,11111067,2995,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
612,624031,1,2,,11111067,2995,Inconclusive,,,7.7543,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
613,624032,1,2,,11111067,2995,Inconclusive,8393992.0,24660.0,0.2751,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
614,624044,1,2,,11111067,2995,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
615,624146,1,1,,90341801,2995,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
616,624147,1,1,,90341801,2995,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
617,624148,1,2,,90341801,2995,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
618,624149,1,1,,90341801,2995,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
619,624170,1,1,,11111067,2995,Inactive,71051501.0,2744.0,12.5893,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
620,624172,1,1,,11111067,2995,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
621,624173,1,3,,11111067,2995,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
622,624296,1,1,,11111067,2995,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
623,624297,1,1,,11111067,2995,Inconclusive,7705682.0,51053.0,14.3194,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
624,624455,1,1,,90341801,2995,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
625,624607,1,9,,103169414,2995,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
626,624608,3,2,,103169414,2995,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
627,624610,1,9,,103169414,2995,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
628,624613,1,9,,103169414,2995,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
629,624696,1,9,,103169414,2995,Unspecified,117228.0,29277.0,,,Mechanism based inhibition of rat cytochrome P450 CYP2C11 measured by 2-alpha and 16-alpha hydroxylation of testosterone,Other,16248836.0,
630,625144,5,5,,103169414,2995,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
631,625145,4,7,,103169414,2995,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
632,625146,5,5,,103169414,2995,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
633,625147,4,7,,103169414,2995,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
634,625148,4,7,,103169414,2995,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
635,625149,4,7,,103169414,2995,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
636,625150,5,5,,103169414,2995,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
637,625151,4,7,,103169414,2995,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
638,625152,4,7,,103169414,2995,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
639,625153,4,7,,103169414,2995,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
640,625154,4,7,,103169414,2995,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
641,625155,4,7,,103169414,2995,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
642,625156,1,9,,103169414,2995,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
643,625157,6,2,,103169414,2995,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
644,625158,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
645,625159,5,5,,103169414,2995,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
646,625160,1,9,,103169414,2995,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
647,625161,4,7,,103169414,2995,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
648,625162,4,7,,103169414,2995,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
649,625163,4,7,,103169414,2995,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
650,625164,1,6,,103169414,2995,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
651,625165,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
652,625166,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
653,625167,5,5,,103169414,2995,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
654,625168,4,7,,103169414,2995,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
655,625169,1,6,,103169414,2995,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
656,625170,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
657,625171,4,7,,103169414,2995,Active,7531135.0,3757.0,27.8497,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
658,625172,4,7,,103169414,2995,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
659,625173,5,5,,103169414,2995,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
660,625174,5,5,,103169414,2995,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
661,625175,5,5,,103169414,2995,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
662,625176,1,9,,103169414,2995,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
663,625177,5,5,,103169414,2995,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
664,625178,5,5,,103169414,2995,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
665,625179,1,9,,103169414,2995,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
666,625180,5,5,,103169414,2995,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
667,625181,5,5,,103169414,2995,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
668,625182,5,5,,103169414,2995,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
669,625183,5,5,,103169414,2995,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
670,625184,5,5,,103169414,2995,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
671,625185,5,5,,103169414,2995,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
672,625186,5,5,,103169414,2995,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
673,625187,5,5,,103169414,2995,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
674,625188,1,9,,103169414,2995,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
675,625189,1,7,,103169414,2995,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
676,625190,4,5,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
677,625191,4,7,,103169414,2995,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
678,625192,4,7,,103169414,2995,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
679,625193,5,5,,103169414,2995,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
680,625194,4,7,,103169414,2995,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
681,625195,4,7,,103169414,2995,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
682,625196,5,6,,103169414,2995,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
683,625197,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
684,625198,4,7,,103169414,2995,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
685,625199,4,7,,103169414,2995,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
686,625200,4,7,,103169414,2995,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
687,625201,4,7,,103169414,2995,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
688,625202,4,7,,103169414,2995,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
689,625203,4,7,,103169414,2995,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
690,625204,4,7,,103169414,2995,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
691,625205,4,7,,103169414,2995,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
692,625206,4,7,,103169414,2995,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
693,625207,4,7,,103169414,2995,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
694,625208,5,5,,103169414,2995,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
695,625209,4,7,,103169414,2995,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
696,625210,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
697,625211,1,6,,103169414,2995,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
698,625212,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
699,625213,4,7,,103169414,2995,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
700,625214,1,9,,103169414,2995,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
701,625215,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
702,625216,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
703,625217,4,7,,103169414,2995,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
704,625218,4,7,,103169414,2995,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
705,625219,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
706,625220,4,7,,103169414,2995,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
707,625221,4,7,,103169414,2995,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
708,625222,4,7,,103169414,2995,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
709,625223,4,7,,103169414,2995,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
710,625224,3,4,,103169414,2995,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
711,625225,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
712,625226,4,7,,103169414,2995,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
713,625227,4,7,,103169414,2995,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
714,625228,4,7,,103169414,2995,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
715,625229,5,5,,103169414,2995,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
716,625230,1,6,,103169414,2995,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
717,625231,4,7,,103169414,2995,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
718,625232,1,9,,103169414,2995,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
719,625233,4,7,,103169414,2995,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
720,625234,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
721,625235,4,7,,103169414,2995,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
722,625236,5,5,,103169414,2995,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
723,625237,4,7,,103169414,2995,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
724,625238,4,7,,103169414,2995,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
725,625239,4,7,,103169414,2995,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
726,625240,1,9,,103169414,2995,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
727,625241,4,7,,103169414,2995,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
728,625242,4,7,,103169414,2995,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
729,625243,5,5,,103169414,2995,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
730,625244,5,5,,103169414,2995,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
731,625245,5,5,,103169414,2995,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
732,625246,1,9,,103169414,2995,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
733,625247,5,5,,103169414,2995,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
734,625248,5,5,,103169414,2995,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
735,625249,5,5,,103169414,2995,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
736,625250,5,5,,103169414,2995,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
737,625251,5,5,,103169414,2995,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
738,625252,4,7,,103169414,2995,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
739,625253,4,7,,103169414,2995,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
740,625254,4,7,,103169414,2995,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
741,625255,4,7,,103169414,2995,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
742,625256,4,7,,103169414,2995,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
743,625257,4,7,,103169414,2995,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
744,625258,4,7,,103169414,2995,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
745,625259,4,7,,103169414,2995,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
746,625260,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
747,625261,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
748,625262,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
749,625263,4,7,,103169414,2995,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
750,625264,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
751,625265,1,6,,103169414,2995,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
752,625266,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
753,625267,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
754,625268,4,2,,103169414,2995,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
755,625268,4,2,,103169414,2995,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
756,625268,4,2,,103169414,2995,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
757,625268,4,2,,103169414,2995,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
758,625269,4,7,,103169414,2995,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
759,625270,4,7,,103169414,2995,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
760,625271,5,5,,103169414,2995,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
761,625272,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
762,625273,4,6,,103169414,2995,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
763,625274,1,6,,103169414,2995,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
764,625275,3,4,,103169414,2995,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
765,625277,1,3,,103169414,2995,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
766,625279,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
767,625280,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
768,625281,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
769,625282,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
770,625283,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
771,625284,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
772,625285,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
773,625286,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
774,625287,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
775,625288,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
776,625289,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
777,625290,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
778,625291,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
779,625292,1,3,,103169414,2995,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
780,635079,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound after 2.5 hrs by PAMPA-BBB assay,Other,22100138.0,
781,637605,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA,Other,22209418.0,
782,639368,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
783,648667,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay,Other,22341944.0,
784,651635,1,3,,90341801,2995,Inconclusive,171543895.0,6311.0,22.3872,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
785,652106,1,1,,90341801,2995,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
786,659472,1,3,,103169414,2995,Unspecified,,,,,Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA,Other,22257026.0,
787,678806,3,6,,103169414,2995,Unspecified,50401224.0,64037.0,80.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake in Octn1-HRPE cells,Confirmatory,10825452.0,
788,679770,1,8,,103169414,2995,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Desipramine: 100 uM) in MDR1-expressing MDCKII cells",Other,12438524.0,
789,680303,1,8,,103169414,2995,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Desipramine: 20 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
790,681116,1,8,,103169414,2995,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,12438524.0,
791,681146,3,6,,103169414,2995,Unspecified,313104181.0,6580.0,5.36,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,9655880.0,
792,681157,3,6,,103169414,2995,Unspecified,81872095.0,24904.0,2.8,Ki,TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes,Confirmatory,7990927.0,
793,681158,3,6,,103169414,2995,Unspecified,81872789.0,29503.0,10.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes,Confirmatory,11502595.0,
794,681159,3,6,,103169414,2995,Unspecified,81872095.0,24904.0,17.5,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes,Confirmatory,11502595.0,
795,681171,3,6,,103169414,2995,Unspecified,313104182.0,6582.0,16.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes,Confirmatory,9260930.0,
796,681584,3,6,,103169414,2995,Unspecified,24212063.0,6581.0,14.0,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells,Confirmatory,10966924.0,
797,681703,1,7,,103169414,2995,Unspecified,8928242.0,29726.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Desipramine: 2500 uM) in OCTN2-expressing HRPE cells",Other,10454528.0,
798,682029,3,6,,103169414,2995,Unspecified,24212062.0,29504.0,68.0,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in OCT3-expressing HRPE cells,Confirmatory,9830022.0,
799,682228,1,7,,103169414,2995,Unspecified,24212062.0,29504.0,,,"TP_TRANSPORTER: inhibition of Guanidine uptake (Guanidine: 35 uM, Desipramine: 5000 uM) in OCT3-expressing HeLa cells",Other,9632645.0,
800,682275,1,7,,103169414,2995,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.025 uM, Desipramine: 500 uM) in OCTN2-expressing HRPE cells",Other,10454528.0,
801,686977,2,1,,49698852,2995,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
802,696005,3,1,,103169414,2995,Unspecified,,,,,Permeability of the compound after 4 hrs by PAMPA assay,Other,23085773.0,
803,699539,1,7,,103169414,2995,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
804,699540,1,7,,103169414,2995,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
805,699541,1,7,,103169414,2995,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
806,720538,1,2,,90341801,2995,Active,220983390.0,410.0,21.3313,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
807,720559,1,2,,90341801,2995,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
808,720572,1,2,,90341801,2995,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
809,720573,1,2,,90341801,2995,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
810,729797,2,5,,103169414,2995,Active,400630.0,6532.0,0.56,IC50,Inhibition of human SERT expressed in HEK293-MSR cells by 5-HT uptake assay,Confirmatory,23385211.0,
811,729812,1,2,,103169414,2995,Inactive,,,,,Induction of apoptosis in human HeLa cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
812,729813,1,3,,103169414,2995,Inactive,,,,,Induction of apoptosis in human DG75 cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
813,729814,1,2,,103169414,2995,Inactive,,,,,Induction of apoptosis in human MUTU-I cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay,Other,23385211.0,
814,729819,1,2,,103169414,2995,Active,,,17.78,IC50,Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
815,729820,1,3,,103169414,2995,Active,,,39.81,IC50,Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
816,729821,1,3,,103169414,2995,Active,,,7.94,IC50,Reduction in cell viability of human MUTU-I cells after 24 hrs by Alamar blue viability assay,Confirmatory,23385211.0,
817,743205,1,1,,90341801,2995,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
818,743205,1,1,,90341801,2995,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
819,743206,1,1,,90341801,2995,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
820,743206,1,1,,90341801,2995,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
821,743207,1,1,,90341801,2995,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
822,743207,1,1,,90341801,2995,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
823,743244,1,1,,90341801,2995,Inconclusive,,,6.3096,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
824,743322,2,1,,174316136,2995,Inactive,,,14.9502,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
825,743323,2,1,,174316136,2995,Inactive,,,2.983,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
826,743324,2,1,,174316136,2995,Inactive,,,21.1177,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
827,743325,2,1,,174316136,2995,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
828,743326,2,1,,174316136,2995,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
829,743327,2,1,,174316136,2995,Inactive,,,5.9518,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
830,751640,3,2,,103169414,2995,Active,128616.0,6530.0,,IC50,Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells after 3 hrs,Confirmatory,23403082.0,
831,751705,1,5,,103169414,2995,Unspecified,128616.0,6530.0,,,Displacement of [125I]RTI55 from human recombinant norepinephrine transporter expressed in MDCK cells at 10 uM after 3 hrs relative to control,Other,23403082.0,
832,773432,2,3,,103169414,2995,Active,128616.0,6530.0,0.0015,IC50,Displacement of [3H]Nisoxetine from human recombinant NET over-expressed in dog MDCK cells,Confirmatory,24012181.0,
833,775111,1,1,,103169414,2995,Active,,,,,"Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test",Other,24035337.0,
834,781326,1,2,,103169414,2995,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
835,781328,1,2,,103169414,2995,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
836,781329,1,2,,103169414,2995,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by other workers,Other,24249037.0,
837,781330,1,2,,103169414,2995,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by potentiometric titration,Other,24249037.0,
838,1056992,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
839,1056993,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
840,1063770,4,2,,103169414,2995,Active,128616.0,6530.0,0.00115,Ki,Displacement of [3H]Nisoxetine from norepinephrine transporter (unknown origin),Confirmatory,24365159.0,
841,1071344,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by BBB-PAMPA,Other,24389509.0,
842,1079931,1,1,,103169414,2995,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
843,1079932,1,1,,103169414,2995,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
844,1079933,1,1,,103169414,2995,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
845,1079934,1,1,,103169414,2995,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
846,1079935,1,1,,103169414,2995,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
847,1079936,1,1,,103169414,2995,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
848,1079937,1,1,,103169414,2995,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
849,1079938,1,1,,103169414,2995,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
850,1079939,1,1,,103169414,2995,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
851,1079940,1,1,,103169414,2995,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
852,1079941,1,1,,103169414,2995,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
853,1079942,1,1,,103169414,2995,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
854,1079943,1,1,,103169414,2995,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
855,1079944,1,1,,103169414,2995,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
856,1079945,1,1,,103169414,2995,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
857,1079946,1,1,,103169414,2995,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
858,1079947,1,1,,103169414,2995,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
859,1079948,1,1,,103169414,2995,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
860,1079949,1,1,,103169414,2995,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
861,1091955,1,2,,103169414,2995,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
862,1091956,1,1,,103169414,2995,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
863,1091957,1,1,,103169414,2995,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
864,1091958,2,1,,103169414,2995,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
865,1117301,1,2,,174316136,2995,Inactive,,,15.8489,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
866,1117302,1,2,,174316136,2995,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
867,1117303,1,2,,174316136,2995,Inactive,,,15.85,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
868,1117311,1,1,,174316136,2995,Inactive,,,15.8489,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
869,1117315,1,1,,174316136,2995,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
870,1117318,1,1,,174316136,2995,Active,,,15.8489,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
871,1129167,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24592867.0,
872,1131083,1,1,,103169414,2995,Unspecified,,,,,Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins,Other,533882.0,
873,1134043,1,1,,103169414,2995,Unspecified,,,,,Antitetrabenazine activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine-induced ptosis challenged with tetrabenazine after 30 mins later and after another 30 mins of drug treatment,Other,850252.0,
874,1135979,2,2,,103169414,2995,Active,341942009.0,20538.0,1.6,IC50,Inhibition of noradrenaline transporter in NMRI albino mouse brain assessed as [3H]NA accumulation in hypothalamus after 5 mins,Confirmatory,22757.0,
875,1135980,2,2,,103169414,2995,Active,341942273.0,15567.0,9.3,IC50,Inhibition of 5-HT transporter in NMRI albino mouse brain assessed as [3H]5-HT accumulation in hypothalamus after 5 mins,Confirmatory,22757.0,
876,1135981,1,2,,103169414,2995,Unspecified,,,,,Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]NA accumulation in hypothalamus after 0.5 hrs,Other,22757.0,
877,1135982,1,2,,103169414,2995,Unspecified,,,,,Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]5-HT accumulation in hypothalamus after 0.5 hrs,Other,22757.0,
878,1135983,1,2,,103169414,2995,Unspecified,,,,,Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]DA accumulation in hypothalamus after 0.5 hrs,Other,22757.0,
879,1135984,1,1,,103169414,2995,Unspecified,,,,,Potentiation of 5-HTP-induced head twitches in ip dosed NMRI albino mouse administered 1 hr prior to 5-HTP challenge,Other,22757.0,
880,1135985,1,1,,103169414,2995,Unspecified,,,,,Mydriatic effect in iv dosed NMRI albino mouse assessed as concentration required to increase pupil diameter by 200%,Other,22757.0,
881,1135986,1,1,,103169414,2995,Unspecified,,,,,Acute toxicity in iv dosed NMRI albino mouse assessed as lethality up to 24 hrs,Other,22757.0,
882,1159387,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
883,1159389,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
884,1159390,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
885,1159391,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
886,1159394,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
887,1159395,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
888,1159396,1,2,,103169414,2995,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
889,1159580,2,1,,268735317,2995,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
890,1159580,2,1,,273002785,2995,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
891,1159607,2,1,,312309792,2995,Active,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
892,1161578,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25156301.0,
893,1167550,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
894,1169140,1,1,,103169414,2995,Unspecified,,,,,Retention time of the compound by EPSA supercritical fluid chromatography,Other,25313332.0,
895,1173449,1,1,,103169414,2995,Unspecified,,,,,Effective permeability of the compound by PAMPA assay,Other,25454267.0,
896,1183278,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25016233.0,
897,1207153,1,2,,103169414,2995,Active,215273881.0,6331.0,1.52,IC50,Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA,Confirmatory,21300721.0,
898,1207182,1,2,,103169414,2995,Active,5921694.0,100135490.0,1.709,IC50,Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes,Confirmatory,21300721.0,
899,1207212,1,1,,103169414,2995,Active,,,1.39,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
900,1207243,1,2,,103169414,2995,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
901,1207635,1,2,,103169414,2995,Active,5921694.0,100135490.0,1.709,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
902,1207636,1,2,,103169414,2995,Active,116412.0,24239.0,11.7,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes,Confirmatory,22761000.0,
903,1210069,1,2,,103169414,2995,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
904,1212314,1,1,,103169414,2995,Unspecified,,,220.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
905,1212341,1,1,,103169414,2995,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
906,1220554,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
907,1220555,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
908,1220556,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
909,1220557,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
910,1220558,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
911,1220559,1,2,,103169414,2995,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
912,1220560,1,1,,103169414,2995,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
913,1222793,1,1,,103169414,2995,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
914,1224859,2,1,,90341801,2995,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
915,1224863,1,1,,316920260,2995,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
916,1224905,2,1,,252566463,2995,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
917,1224905,2,1,,252566463,2995,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
918,1230203,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound using PDVF membrane after 2 hrs 45 mins by PAMPA-BBB assay,Other,26030662.0,
919,1230204,1,1,,103169414,2995,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,26030662.0,
920,1259325,1,2,,336954348,2995,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
921,1259370,2,2,,124671360,2995,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
922,1259370,2,2,,124671360,2995,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
923,1259370,2,2,,124671360,2995,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
924,1259389,1,1,,124671360,2995,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
925,1259407,1,1,,363905041,2995,Inactive,,,,,CCRIS mutagenicity studies,Other,,
926,1259410,1,1,,363905041,2995,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
927,1259416,1,2,,375174778,2995,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
928,1259421,1,1,,375174778,2995,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
929,1259423,1,2,,354810084,2995,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
930,1259423,1,2,,354923399,2995,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
931,1259423,1,2,,354929424,2995,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
932,1259423,1,2,,354940643,2995,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
933,1259423,1,2,,355007130,2995,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
